Dr Abdou on Sequencing CDK4/6 Inhibitors in HER2– Metastatic Breast Cancer

Yara Abdou, MD, discusses findings from the phase 2 MAINTAIN trial in patients with HER2-negative metastatic breast cancer, as well as the clinical implications of these trial results.

Related Keywords

Yara Abdou ,Department Of Medicine ,University Of North Carolina School Medicine ,Division Of Oncology ,North Carolina School ,D ,Maintain Trial ,Nct02632045 ,Patients With Her2 Negative Metastatic Breast Cancer ,